Novel strategies for reversing platinum resistance

被引：66

作者：

Shahzad, Mian M. K. ^{[1
,2
]}

Lopez-Berestein, Gabriel ^{[3
,4
,5
]}

Sood, Anil K. ^{[1
,4
,5
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77030 USA

[2] Baylor Coll Med, Dept Obstet & Gynecol, Houston, TX 77030 USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA

[4] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA

[5] Univ Texas MD Anderson Canc Ctr, Ctr RNA Interference & Noncoding RNA, Houston, TX 77030 USA

来源：

DRUG RESISTANCE UPDATES | 2009年 / 12卷 / 06期

关键词：

ATP7B; Cisplatin; Chemoresistance; Drug transport; Kinases; MK-0457; Ovarian cancer; siRNA; Tumor stroma; BRCA1; EPITHELIAL OVARIAN-CANCER; ADENOSINE-TRIPHOSPHATASE ATP7B; EXTRACELLULAR-MATRIX PROTEINS; NUCLEOTIDE EXCISION-REPAIR; MEDIATED DRUG-RESISTANCE; INTERFERING RNA DELIVERY; SUPPRESSES TUMOR-GROWTH; TARGETING AURORA KINASE; CELL LUNG-CANCER; IN-VIVO;

D O I：

10.1016/j.drup.2009.09.001

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Platinum-based drugs continue to be the mainstay of therapy for ovarian cancer. Along with adverse effects, chemoresistance (intrinsic or acquired) has become a major limitation in the management of recurrent disease. Even though much is known about the effects of platinum drugs on cancer cells, the mechanisms underlying resistance are poorly understood. In this review, we summarize the current data on chemoresistance and discuss novel strategies to reverse resistance to platinum-based drugs. The most important targets highlighted here include Aurora kinases, PARP, ATP7B, and ERCC1. Furthermore, we discuss the implications of these novel approaches for ovarian cancer treatment. (C) 2009 Elsevier Ltd. All rights reserved.

引用

页码：148 / 152

页数：5

共 76 条

[1] Ovarian cancer: Strategies for overcoming resistance to chemotherapy [J].

Agarwal, R ;

Kaye, SB .

NATURE REVIEWS CANCER, 2003, 3 (07) :502-516

[2] The PARP superfamily [J].

Amé, JC ;

Spenlehauer, C ;

de Murcia, G .

BIOESSAYS, 2004, 26 (08) :882-893

[3] AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol [J].

Anand, S ;

Penrhyn-Lowe, S ;

Venkitaraman, AR .

CANCER CELL, 2003, 3 (01) :51-62

[4] SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo [J].

Arbitrario, Jennifer P. ;

Belmont, Brian J. ;

Evanchik, Marc J. ;

Flanagan, W. Michael ;

Fucini, Raymond V. ;

Hansen, Stig K. ;

Harris, Shannon O. ;

Hashash, Ahmad ;

Hoch, Ute ;

Hogan, Jennifer N. ;

Howlett, Anthony R. ;

Jacobs, Jeffrey W. ;

Lam, Joni W. ;

Ritchie, Sean C. ;

Romanowski, Michael J. ;

Silverman, Jeffrey A. ;

Stockett, David E. ;

Teague, Juli N. ;

Zimmerman, Kristin M. ;

Taverna, Pietro .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 65 (04) :707-717

[5] BMS-536924 sensitizes human epithelial ovarian cancer cells to the PARP inhibitor, 3-aminobenzamide [J].

Beauchamp, Marie-Claude ;

Knafo, Ariane ;

Yasmeen, Amber ;

Carboni, Joan M. ;

Gottardis, Marco M. ;

Pollak, Michael N. ;

Gotlieb, Walter H. .

GYNECOLOGIC ONCOLOGY, 2009, 115 (02) :193-198

[6] How do real tumors become resistant to cisplatin? [J].

Borst, Piet ;

Rottenberg, Sven ;

Jonkers, Jos .

CELL CYCLE, 2008, 7 (10) :1353-1359

[7] Modifications of DNA by platinum complexes - Relation to resistance of tumors to platinum antitumor drugs [J].

Brabec, V ;

Kasparkova, J .

DRUG RESISTANCE UPDATES, 2005, 8 (03) :131-146

[8] Aurora kinases: New targets for cancer therapy [J].

Carvajal, Richard D. ;

Tse, Archie ;

Schwartz, Gary K. .

CLINICAL CANCER RESEARCH, 2006, 12 (23) :6869-6875

[9] Role of ERCC1 promoter hypermethylation in drug resistance to cisplatin in human gliomas [J].

Chen, Hua-Yun ;

Shao, Cui-Jie ;

Chen, Fu-Rong ;

Kwan, Aij-Lie ;

Chen, Zhong-Ping .

INTERNATIONAL JOURNAL OF CANCER, 2010, 126 (08) :1944-1954

[10] Base excision repair is impaired in mammalian cells lacking poly(ADP-ribose) polymerase-1 [J].

Dantzer, F ;

de la Rubia, G ;

Murcia, JMD ;

Hostomsky, Z ;

de Murcia, G ;

Schreiber, V .

BIOCHEMISTRY, 2000, 39 (25) :7559-7569

← 1 2 3 4 5 6 7 8 →